Repros Reports Results From Completed 1 mg Dose Cohort in Low Dose Proellex Study

Repros Therapeutics Inc. RPRX today announced it has completed its internal review of the results obtained for the 1 mg dose from its low dose study of Proellex®. No signals of liver toxicity or drug related adverse events were detected over the 10 week dosing period.

Twelve women were enrolled in the study and 11 women completed the trial. The one woman that discontinued left the study because she was not able to visit the clinical site weekly, as prescribed by the protocol.